Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nipro: SURELYZER PES-a
March 12, 2007
- Results of JPHC Study Announced
March 12, 2007
- Synergy NeuroStimulator from Medtronic, A New Option for Severe Chronic Pain: Dr Abe
March 12, 2007
- DSP to Start 3-Year Approach Run to Go Fully Global: Mr Miyatake
March 12, 2007
- GSK Launches New OTC Sleep Inducer
March 12, 2007
- Nippon Organon to Launch a Series of Major New Products: Mr van Eerd
March 12, 2007
- SELF-MEDICATION NEWS IN BRIEF
March 12, 2007
- Preminent Maintains Top Position: Rep Track Survey
March 12, 2007
- Pfizer Japan Needs Flat, Agile Organization: Mr Iwasaki
March 12, 2007
- DSM to Expand Its Business in Life Sciences
March 12, 2007
- BUSINESS NEWS IN BRIEF
March 12, 2007
- APDD Kicks Off Symposium on Microdosing Studies ―１―
March 12, 2007
- APDD Kicks Off Symposium on Microdosing Studies ―２―
March 12, 2007
- Post-Marketing Clinical Trials to Increase: JCROA Seminar
March 12, 2007
- R&D NEWS IN BRIEF
March 12, 2007
- Prefectural Health Policy Officials' Conference
March 12, 2007
- 4 NME-Based Drugs, 1 New Combination Recommended for Approval
March 5, 2007
- Norvasc Most Often Prescribed as 1st-Line: EPOCA Marketing
March 5, 2007
- Avastin Recommended for Approval
March 5, 2007
- No Jobs Will Be Cut in Japan: Mr Brennan of AstraZeneca
March 5, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…